Thromboembolism prophylaxis after biologic aortic valve replacement (BAVR) is recommended for 3 months postoperatively. We examined the continuation of oral anticoagulation (OAC) treatment and its effect on the long-term prognosis after BAVR. We used nation-wide register data from 4,079 individuals who underwent BAVR.
View Article and Find Full Text PDFObjectives: Women are considered to have poorer prognoses after cardiac surgery, although evidence is scarce. The authors studied sex differences and long-term outcomes after surgical aortic valve replacement (SAVR).
Design: Nationwide retrospective cohort study.
Scand Cardiovasc J
February 2020
. To investigate nationwide changes in procedure rates, patient selection, and prognosis after all surgical aortic valve replacements. .
View Article and Find Full Text PDFBackground: Biologic prostheses are preferred for surgical aortic valve replacement (SAVR) in patients more than 70 years of age in clinical practice. This study investigated differences in long-term outcomes between SAVR-treated patients more than 70 years of age who received mechanical or biologic prosthetic valves.
Methods: All patients (excluding those with endocarditis) who were more than 70 years of age and who underwent isolated first-time SAVR (with or without coronary artery bypass grafting) in Finland between 2004 and 2014 were retrospectively studied (n = 4227).
Objectives: Contemporary, nationwide data on trends in mitral valve surgery are scarce. Our aim was to investigate changes in procedure rates, patient selection, and post-procedural prognosis of open-heart mitral valve surgery in Finland.
Design: We combined data from three nationwide administrative registers with compulsory reporting.